Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck

被引：0
|
作者：
Jacques Bernier
机构：
[1] Genolier,J Bernier is Chairman of the Radio
[2] Switzerland.,Oncology Division at the Genolier Swiss Medical Network
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck have a poor prognosis. Cetuximab represents a clinically relevant advance in the treatment of recurrent and metastatic disease. This rationale for cetuximab as monotherapy and its use in combination with platinum-based chemotherapy for recurrent and/or metastatic disease in the first-line setting is discussed.
引用
收藏
页码：705 / 713
页数：8
相关论文
共 50 条
  • [21] Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Hsieh, Ronan W.
    Borson, Steven
    Tsagianni, Anastasia
    Zandberg, Dan P.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck
    Saada-Bouzid, Esma
    Peyrade, Frederic
    Guigay, Joel
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (03) : 146 - 151
  • [23] Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck
    Fanucchi, M
    Khuri, FR
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 809 - 815
  • [24] Intra-arterial cetuximab for the treatment of recurrent unresectable head and neck squamous cell carcinoma
    Tham, Tristan
    White, Timothy G.
    Chakraborty, Shamik
    Lall, Rohan R.
    Ortiz, Rafael
    Langer, David J.
    Shatzkes, Deborah
    Filippi, Christopher G.
    Kraus, Dennis
    Boockvar, John A.
    Costantino, Peter D.
    JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, 2016, 11 (04) : 293 - 301
  • [25] Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
    Bernier, Jacques
    ONCOLOGY REVIEWS, 2009, 3 (04) : 247 - 256
  • [26] Weekly Paclitaxel plus Cetuximab in the primary treatment of metastatic/recurrent squamous cell cancer of head and neck
    Taira, Shinichiro
    Nakano, Kenji
    Tomomatsu, Junichi
    Marshall, Shouko
    Takahashi, Shunji
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] Methotrexate and cetuximab for metastatic advanced head and neck squamous cell carcinoma.
    Atassi, Bassel
    Yoo, George H.
    Robinette, Natasha
    Sibai, Khaled
    Sukari, Ammar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US.
    Nadler, Eric S.
    Joo, Seongjung
    Black-Shinn, Jenny
    Boyd, Marley
    Zhuo, Joseph
    Chirovsky, Diana Romana
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    Argiris, A.
    Kotsakis, A. P.
    Hoang, T.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Gyanchandani, R.
    Blumenschein, G. R., Jr.
    Chen, H. X.
    Grandis, J. R.
    Harari, P. M.
    Kies, M. S.
    Kim, S.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 220 - 225
  • [30] Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Bhatia, Aarti
    Mehra, Ranee
    Bauman, Jessica
    Khan, Saad A.
    Wei, Wei
    Neumeister, Veronique
    Sandoval-Schaefer, Teresa
    Alpaugh, R. Katherine
    Lango, Miriam
    Rimm, David L.
    Ridge, John A.
    Burtness, Barbara
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,
12345